Business Wire

IDEMIA Appoints Pierre Barrial as President & Chief Executive Officer of the Group

Share

The supervisory board of IDEMIA has appointed Pierre Barrial as the new President & CEO of the Group, replacing Yann Delabrière who resumes his previous role as Chairman of the Board. Matthew Cole, who has joined the Group, has taken on Pierre Barrial’s previous position as head of the Secure Enterprise Transactions (SET) division.

Over the last 18 months, IDEMIA has restored its growth and cash generation performance after the creation and successful integration of IDEMIA. Yann, who became President & CEO on October 18th 2018, will now be returning to his role as Chairman of the Board with effect from July 1st, 2020, where he will continue to contribute his strategic and governance insights to the company.

Pierre Barrial will succeed Yann as the Group’s President & CEO. He brings over 25 years’ experience with multinational and multicultural tech companies serving both the government and enterprise sectors. Pierre was in charge of SET, having previously managed IDEMIA’s Mobile Operators then Financial Institutions activities, both today part of the SET division. He has partnered with Yann since the beginning of the year as Deputy CEO. Pierre will become IDEMIA’s Group President & CEO starting July 1st, 2020.

Matthew Cole is appointed as head of the SET division, replacing Pierre Barrial. Matthew brings a wealth of experience in this space, having been President of Cubic Transportation Systems, the leading integrator of payment and information solutions and related services for intelligent travel applications in the transportation industry. He will be based in the US and will sit on the Group Executive Committee, as SET division’s CEO.

Yann Delabrière stated: “After a carefully prepared succession plan, we have chosen a world-class executive, Pierre Barrial, to manage the Group. IDEMIA has demonstrated remarkable resilience since the beginning of this year and our business fundamentals are strong and bode well for the future. On behalf of the Board, I wish Pierre all the very best in his new role.”

Pierre Barrial added: “I’m honored and excited to have been chosen as CEO of the Group. IDEMIA has an extremely committed team of 15,000 employees worldwide and together, we’ll continue to serve our clients regardless of the circumstances. I am also proud to head a company whose purpose, since its creation, is to make the world a safer place, whenever and wherever Identity & Security matter in an increasingly digital world. With recent events, this is more true than ever.”

Matthew Cole said: “I am thrilled and proud to join IDEMIA as CEO of the SET division. I plan to work hand in hand with my teams and Group senior management to bring the company’s strategy and growth targets to fruition.”

About Yann Delabrière
Yann Delabrière is a graduate of Ecole Normale Supérieure and Ecole Nationale d’Administration and has a postgraduate degree in mathematics. He began his career at the Committee of Public Accounts (Cour des Comptes) before working for the French External Trade Minister. He then became Chief Financial Officer for the French export credit agency, COFACE, followed by Printemps Group, before becoming Chief Financial Officer for PSA Peugeot Citroën in 1990 and, from 1998, was Chairman and Chief Executive Officer of Banque PSA Finance and sat on the PSA Peugeot Citroën Executive Committee. In 2007 Yann was appointed Chairman and Chief Executive Officer of Faurecia. From June 2017 to February 2018, he chaired the Zodiac Aerospace executive board. From 2004 to May 2018 he was a director of Cap Gemini, from 2012 to 2016 a director of Société Générale and since March 2017 has been a director of Alstom. He has chaired the IDEMIA executive board since October 2018 having previously chaired the IDEMIA supervisory board for a 10-month period.

About Pierre Barrial
Pierre Barrial graduated from Paris School of Business. He comes with over 25 years experience with multinational and multicultural firms and agencies from a broad array of industries including ICT and security, serving both the public and private sectors. After Pierre joined IDEMIA in 2013, he managed the Group’s Latin American operations followed by the Mobile Operators business, the Financial Institutions business and SET. Previously, Pierre worked in various jobs for Bull Group in South Africa, Italy, Poland and Brazil.

About Matthew Cole
Matthew Cole holds an MBA from Oxford Brookes University and is also Chartered Certified Accountant. In 2003 he joined Cubic Corporation, the world leader in smart and contactless payments for transportation. During his time at Cubic Matthew held several senior finance positions before successfully heading up the company’s Asia-Pacific operations followed by global Strategy and Business Development. In 2015, he became President of Cubic Transportation Systems. Before Cubic Corporation, Matthew held several positions with blue-chip multinational firms including Endemol, British Airways, Mitsui, First Choice and Schlumberger.

About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.

Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.

For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press:
Hanna Sebbah
idemia@havas.com
+33 (0) 6 63 73 30 30

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release

Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye